Serprozyme ApS: Financial statements 2025
CVR: 44083205
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Serprozyme ApS (CVR 44083205) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 168,506 and a net result of DKK 131,445 compared with DKK 24,507 the year before. That is an increase of 443% compared with the year before. Equity in the 2025 report amounted to DKK 193,766. The solvency ratio was 84%.
- Gross Profit
- DKK 168,506
- Profit/Loss
- DKK 131,445
- Equity
- DKK 193,766
- Total Assets
- DKK 230,726
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 169 t. | 131 t. | 194 t. | 0 |
| 2024 | - | 31 t. | 25 t. | 62 t. | 0 |
How creditworthy is Serprozyme ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Serprozyme ApS has published its annual report for 2024. Gross profit came to DKK 31,033, and the net result was DKK 24,507.
About Serprozyme ApS
Serprozyme ApS is a Danish company of the type Anpartsselskab based in Randers SV, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Jan Kristian Jensen. The company is owned by Emvijo Initiative ApS and Jan Kristian Jensen Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 168,506 and a net result of DKK 131,445 compared with DKK 24,507 the year before. Equity in the 2025 report amounted to DKK 193,766.